Gui Junhong, Liu Boyi, Cao Guan, Lipchik Andrew M, Perez Minervo, Dekan Zoltan, Mobli Mehdi, Daly Norelle L, Alewood Paul F, Parker Laurie L, King Glenn F, Zhou Yufeng, Jordt Sven-Eric, Nitabach Michael N
Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06520, USA; Department of Genetics, Yale School of Medicine, New Haven, CT 06520, USA; Program in Cellular Neuroscience, Neurodegeneration, and Repair, Yale School of Medicine, New Haven, CT 06520, USA.
Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
Curr Biol. 2014 Mar 3;24(5):473-83. doi: 10.1016/j.cub.2014.01.013. Epub 2014 Feb 13.
The venoms of predators have been an excellent source of diverse highly specific peptides targeting ion channels. Here we describe the first known peptide antagonist of the nociceptor ion channel transient receptor potential ankyrin 1 (TRPA1).
We constructed a recombinant cDNA library encoding ∼100 diverse GPI-anchored peptide toxins (t-toxins) derived from spider venoms and screened this library by coexpression in Xenopus oocytes with TRPA1. This screen resulted in identification of protoxin-I (ProTx-I), a 35-residue peptide from the venom of the Peruvian green-velvet tarantula, Thrixopelma pruriens, as the first known high-affinity peptide TRPA1 antagonist. ProTx-I was previously identified as an antagonist of voltage-gated sodium (NaV) channels. We constructed a t-toxin library of ProTx-I alanine-scanning mutants and screened this library against NaV1.2 and TRPA1. This revealed distinct partially overlapping surfaces of ProTx-I by which it binds to these two ion channels. Importantly, this mutagenesis yielded two novel ProTx-I variants that are only active against either TRPA1or NaV1.2. By testing its activity against chimeric channels, we identified the extracellular loops of the TRPA1 S1-S4 gating domain as the ProTx-I binding site.
These studies establish our approach, which we term "toxineering," as a generally applicable method for isolation of novel ion channel modifiers and design of ion channel modifiers with altered specificity. They also suggest that ProTx-I will be a valuable pharmacological reagent for addressing biophysical mechanisms of TRPA1 gating and the physiology of TRPA1 function in nociceptors, as well as for potential clinical application in the context of pain and inflammation.
捕食者的毒液是多种靶向离子通道的高度特异性肽的优质来源。在此,我们描述了伤害感受器离子通道瞬时受体电位锚蛋白1(TRPA1)的首个已知肽拮抗剂。
我们构建了一个重组cDNA文库,其编码约100种源自蜘蛛毒液的不同糖基磷脂酰肌醇(GPI)锚定肽毒素(t-毒素),并通过在非洲爪蟾卵母细胞中与TRPA1共表达来筛选该文库。此筛选鉴定出原毒素-I(ProTx-I),这是一种来自秘鲁绿绒蜘蛛(Thrixopelma pruriens)毒液的35个氨基酸残基的肽,是首个已知的高亲和力肽TRPA1拮抗剂。ProTx-I先前被鉴定为电压门控钠(NaV)通道的拮抗剂。我们构建了ProTx-I丙氨酸扫描突变体的t-毒素文库,并针对NaV1.2和TRPA1筛选该文库。这揭示了ProTx-I与这两种离子通道结合的不同且部分重叠的表面。重要的是,这种诱变产生了两种仅对TRPA1或NaV1.2有活性的新型ProTx-I变体。通过测试其对嵌合通道的活性,我们确定了TRPA1 S1-S4门控结构域的细胞外环为ProTx-I结合位点。
这些研究确立了我们称为“毒素工程”的方法,作为分离新型离子通道调节剂和设计具有改变特异性的离子通道调节剂的普遍适用方法。它们还表明,ProTx-I将是一种有价值的药理学试剂,可用于研究TRPA1门控的生物物理机制和伤害感受器中TRPA1功能的生理学,以及在疼痛和炎症方面的潜在临床应用。